Results 31 to 40 of about 3,282 (184)

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

Cancer Medicine, 2020
Purpose To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on ...
Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, Akihiko Osaki, Toshimi Takano, Yoichi Naito, Kazuo Matsuura, Kenjiro Aogi, Kimiko Fujiwara, Kenji Tamura, Motoi Baba, Shinya Tokunaga, Gen Hirano, Shigeru Imoto, Chieko Miyazaki, Kazuhiro Yanagihara, Chiyo K. Imamura, Yasutaka Chiba, Toshiaki Saeki   +18 more
doaj   +1 more source

A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients.

PLoS ONE, 2020
BackgroundPostoperative nausea and vomiting (PONV) is a common postsurgical complication. Palonosetron is effective for PONV prevention at the usual dose of 75 μg, but the ideal dose for obese patients has not yet been investigated. The aim of this study
Nathalia Gouveia de Araujo Ferreira, Ismar Lima Cavalcanti, Alexandra Rezende Assad, Louis Barrucand, Estêvão Luiz Carvalho Braga, Nubia Verçosa   +5 more
doaj   +1 more source

Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery

Current Therapeutic Research, 2019
: Background: Postoperative nausea and vomiting (PONV) are 2 of the most frequent adverse effects of anesthesia. PONV prolongs hospital stays and also delays the recovery of patients.
Ahmet Aydin, MD, Mustafa Kaçmaz, MD, Adem Boyaci, MD   +2 more
doaj   +1 more source

An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity

Pharmaceuticals, 2020
Cisplatin is widely used to treat various types of cancers, but it is often limited by nephrotoxicity. Here, we employed an integrated in silico and in vivo approach to identify potential treatments for cisplatin-induced nephrotoxicity (CIN).
Eri Wakai, Yuya Suzumura, Kenji Ikemura, Toshiro Mizuno, Masatoshi Watanabe, Kazuhiko Takeuchi, Yuhei Nishimura   +6 more
doaj   +1 more source

Seizure associated with palonosetron

Supportive Care in Cancer, 2009
In 2003, FDA approved palonosetron as an effective drug for the control ofnausea and vomitingassociated tochemotherapy. Palonosetron is suggested in case of emetogenic chemotherapy schedules, in particular, in the case of cisplatin, high-dose cyclophosphamide, and anthracyclines.
Zambelli A, Sagrada P, Pavesi L
openaire   +3 more sources

Impact of 5-HT₃ receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

BMC Health Services Research, 2012
Background 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2nd generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and ...
Lin Swu-Jane, Hatoum Hind T, Buchner Deborah, Cox David, Balu Sanjeev   +4 more
doaj   +1 more source

Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy [PDF]

Korean Journal of Anesthesiology, 2013
BackgroundPalonosetron is a recently introduced 5-hydroxytryptamine-3 (5-HT3) receptor antagonist useful for postoperative nausea and vomiting prophylaxis.
Jeong Jin Min, Yongjae Yoo, Tae Kyong Kim, Jung-Man Lee   +3 more
doaj   +1 more source

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

BMC Pharmacology and Toxicology, 2019
Background Nausea is more difficult to control than vomiting in chemotherapy. We therefore analyzed the efficacy of a strong supportive treatment with aprepitant, palonosetron, and dexamethasone against nausea for various moderately emetogenic ...
Naohisa Yoshida, Tetsuya Taguchi, Masayoshi Nakanishi, Ken Inoue, Tetsuya Okayama, Takeshi Ishikawa, Eigo Otsuji, Koichi Takayama, Haruo Kuroboshi, Motohiro Kanazawa, Yoshito Itoh   +10 more
doaj   +1 more source

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

Cancer Management and Research, 2009
Rudolph M NavariIndiana University School of Medicine South Bend, South Bend, IN USAAbstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life.
Rudolph M Navari
doaj  

Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life.
Abdul Aslam Parathoduvil, Asha Sisupalan, Padanayil Lekshmikutty Rema   +2 more
doaj   +1 more source